[
  {
    "ts": null,
    "headline": "BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival",
    "summary": "BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival",
    "url": "https://finnhub.io/api/news?id=939f59a489b60cd030c04e8d1404e5a9b1f8333ec62ff2e4dacae2ccffb3d66b",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759163082,
      "headline": "BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival",
      "id": 136923973,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival",
      "url": "https://finnhub.io/api/news?id=939f59a489b60cd030c04e8d1404e5a9b1f8333ec62ff2e4dacae2ccffb3d66b"
    }
  },
  {
    "ts": null,
    "headline": "GSK Will Replace CEO Walmsley With a Company Insider. The Stock Is Up.",
    "summary": "Emma Walmsley has overseen eight turbulent years at he U.K. drugmaker. The firm announced Monday that she will be succeeded by GSK insider and drug industry stalwart Luke Miels.",
    "url": "https://finnhub.io/api/news?id=1c1eb0a4265aac1516d8929b9b62497fca4a773dbf0787d2b75a71343705852f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759159080,
      "headline": "GSK Will Replace CEO Walmsley With a Company Insider. The Stock Is Up.",
      "id": 136915724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Emma Walmsley has overseen eight turbulent years at he U.K. drugmaker. The firm announced Monday that she will be succeeded by GSK insider and drug industry stalwart Luke Miels.",
      "url": "https://finnhub.io/api/news?id=1c1eb0a4265aac1516d8929b9b62497fca4a773dbf0787d2b75a71343705852f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Likely To Pass The Drug Import Tariff Stress Test",
    "summary": "Pfizer's strong pipeline of drugs and its fortress balance sheet make it an attractive investment at cheap valuation multiples. Click to read why PFE is a Buy.",
    "url": "https://finnhub.io/api/news?id=a3e117fc4983f97927fea4c7e48ba7d3112a13366e0dbfe6117c45d7a0226f3b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759158961,
      "headline": "Pfizer Is Likely To Pass The Drug Import Tariff Stress Test",
      "id": 136917778,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's strong pipeline of drugs and its fortress balance sheet make it an attractive investment at cheap valuation multiples. Click to read why PFE is a Buy.",
      "url": "https://finnhub.io/api/news?id=a3e117fc4983f97927fea4c7e48ba7d3112a13366e0dbfe6117c45d7a0226f3b"
    }
  },
  {
    "ts": null,
    "headline": "3 Of My Favorite Biotech Stocks Under $10",
    "summary": "Discover 3 top biotech stocks under $10 with lucrative options for covered call strategies. Click for these under-the-radar stocks that could fly.",
    "url": "https://finnhub.io/api/news?id=956d7ca02fef0fb71847d3f0160659ce25fe440c9f8c6c613e7e70dbb7de075a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759151709,
      "headline": "3 Of My Favorite Biotech Stocks Under $10",
      "id": 136917072,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295160689/image_1295160689.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover 3 top biotech stocks under $10 with lucrative options for covered call strategies. Click for these under-the-radar stocks that could fly.",
      "url": "https://finnhub.io/api/news?id=956d7ca02fef0fb71847d3f0160659ce25fe440c9f8c6c613e7e70dbb7de075a"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock",
    "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=dc134237c53289b910099ccdaab6eeb4358673e2b9af27d57b37a523f693fd68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759150804,
      "headline": "Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock",
      "id": 136915861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=dc134237c53289b910099ccdaab6eeb4358673e2b9af27d57b37a523f693fd68"
    }
  },
  {
    "ts": null,
    "headline": "Cheapest S&P 500 Stocks Ranked: 30 Best Value Buys",
    "summary": "Discover 30 top large-cap stocks offering strong value and quality.",
    "url": "https://finnhub.io/api/news?id=128fd721f9f6e5596b2df433e7890d99c8fbaabc25a5e6304c77ff2d7740de20",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759141719,
      "headline": "Cheapest S&P 500 Stocks Ranked: 30 Best Value Buys",
      "id": 136915123,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189068007/image_2189068007.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover 30 top large-cap stocks offering strong value and quality.",
      "url": "https://finnhub.io/api/news?id=128fd721f9f6e5596b2df433e7890d99c8fbaabc25a5e6304c77ff2d7740de20"
    }
  },
  {
    "ts": null,
    "headline": "As obesity M&A heats up, pharmas could get ‘blinded by opportunity’",
    "summary": "With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.",
    "url": "https://finnhub.io/api/news?id=a1d8f8a7efc5de2300d4204e505fd5f857e8433023da8bf00e1180be42da0f62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759133957,
      "headline": "As obesity M&A heats up, pharmas could get ‘blinded by opportunity’",
      "id": 136914591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.",
      "url": "https://finnhub.io/api/news?id=a1d8f8a7efc5de2300d4204e505fd5f857e8433023da8bf00e1180be42da0f62"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
    "summary": "Right now, these dividend payers are top options for folks who like to set it and forget it.",
    "url": "https://finnhub.io/api/news?id=8238ce38424da76c1d85531a97a0ac9de46a50e0bc0ea20c7ad5eaed4ee11334",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759131780,
      "headline": "3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
      "id": 136913721,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Right now, these dividend payers are top options for folks who like to set it and forget it.",
      "url": "https://finnhub.io/api/news?id=8238ce38424da76c1d85531a97a0ac9de46a50e0bc0ea20c7ad5eaed4ee11334"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Maintains a Buy on Pfizer Inc (PFE), Keeps the PT",
    "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer Inc. (NYSE:PFE) with a price target of $30. ​The analyst pointed to the company’s recent acquisition of Metsera. He noted that the deal allows […]",
    "url": "https://finnhub.io/api/news?id=d0dc747e97289ec5b10e96de8579e89aff04515dcd91534394b476581008f7c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759124375,
      "headline": "BMO Capital Maintains a Buy on Pfizer Inc (PFE), Keeps the PT",
      "id": 136913588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer Inc. (NYSE:PFE) with a price target of $30. ​The analyst pointed to the company’s recent acquisition of Metsera. He noted that the deal allows […]",
      "url": "https://finnhub.io/api/news?id=d0dc747e97289ec5b10e96de8579e89aff04515dcd91534394b476581008f7c8"
    }
  }
]